Immune system protects the human body from disease and infection. However incase of autoimmune disease, immune system attacks healthy cells in the body by mistake. There are many systemic disorders with possible involvement of the nervous system with presumed inflammatory and autoimmune pathomechanisms. Abnormal inflammatory response is closely associated with in autoimmune diseases. These inflammations cause impaired functioning, resulting in neurological or psychiatric symptoms. Multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome are some of the most well known neurological diseases induced by abnormal autoimmunity.
The exact cause of immune-system misfire is unknown although some people are more likely to get an autoimmune disease than others. Certain autoimmune diseases, like multiple sclerosis and lupus is hereditary. Not every family member will necessarily have the disease, but they inherit a susceptibility to an autoimmune condition. As the incidence of autoimmune diseases is rising, researchers are also investigating environmental risk factors like infections and exposure to chemicals. Autoimmune disorders of the nervous system may affects both CNS and PNS, including the brain, spinal cord, peripheral nerves, neuromuscular junction and skeletal muscle.
Market Analysis: The global autoimmune disease therapeutics market was worth $109,833 million in 2017, and is expected to grow at a CAGR of 4.2 percent from 2018 to 2025, to reach $153,320 million. An autoimmune illness is a condition in which the immune system attacks and destroys its own body tissue. During the forecast period, the autoimmune disease diagnostics market is expected to grow at a CAGR of roughly 8.3%. Rising global awareness of autoimmune disorders as a result of research, education, support, and advocacy activities is a major reason driving up the use of autoimmune disease diagnostics. The global autoimmune disease diagnosis market is estimated to increase at a CAGR of 8.9% from USD 4.1 billion in 2020 to USD 6.3 billion in 2025. The global autoimmune disease therapeutics market was worth $109,833 million in 2017, and is expected to grow at a CAGR of 4.2 percent from 2018 to 2025, to reach $153,320 million. From 2018 to 2025, the global autoimmune disease treatments market is estimated to increase at a CAGR of 4.2 percent, from about $109.83 billion in 2017 to $153.32 billion in 2025.
ALSO READ Neurology Neurosurgery Neuroscience Neuropsychiatry Pain Disorder and Management Central Nervous System Pediatric Neurology Neuro-Oncology and Brain Tumors Neurophysiology Neuroimmunology Neuropathology Neuroimaging Neurodegenerative disease and Neurodegeneration Neurological Disorders Sleep Disorder Stroke Movement Disorders Parkinsons disease Epilepsy Multiple Sclerosis Alzheimers Disease and Dementia Neuromuscular Disease Case studies and Clinical trials Novel Treatment Strategies Speech Disorders Demyelinating Disorders Cerebrovascular Disorders Autoimmune and Inflammatory Disorders Neuropathy Headache and Facial Pain Diagnosis and Screening of Neurological Disorders Neurology Critical Care Neuropharmacology and Neurochemistry Stem Cells and Neuroregeneration Cognitive Neuroscience Motor System Disorders
Muscular Dystrophy Conferences Child Psychology Conferences Neurology Conferences 2022 Dementia Conferences Neuroscience Conferences 2021 Dubai Neurology Conferences 2022 Europe Neurology Conferences Europe Cerebrovascular Disease Conferences Neurology Conferences 2022 Asia Neurological Disorders Conferences Neurology Conferences 2022 Sleep Disorders Conferences Neurosurgery Conferences Seizures Conferences Brain Cancer Conferences